Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Medtronic
McKinsey
Harvard Business School
McKesson

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR DEXAMETHASONE ACETATE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Dexamethasone Acetate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003213 ↗ Drugs to Reduce the Side Effects of Chemotherapy Completed Swiss Group for Clinical Cancer Research Phase 3 1996-05-01 RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients treated with chemotherapy. It is not known whether receiving dexamethasone with granisetron is more effective than receiving dexamethasone with metoclopramide for reducing the side effects of chemotherapy. PURPOSE: Randomized phase III trial to compare the effectiveness of dexamethasone with either granisetron or metoclopramide in patients treated with chemotherapy.
NCT00091260 ↗ CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis Completed Celgene Corporation Phase 2 2004-01-01 RATIONALE: Drugs such as CC-5013 and dexamethasone may be effective in treating primary systemic amyloidosis. PURPOSE: This phase II trial is studying CC-5013 to see how well it works with or without dexamethasone in treating patients with primary systemic amyloidosis.
NCT00091260 ↗ CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis Completed Vaishali Sanchorawala Phase 2 2004-01-01 RATIONALE: Drugs such as CC-5013 and dexamethasone may be effective in treating primary systemic amyloidosis. PURPOSE: This phase II trial is studying CC-5013 to see how well it works with or without dexamethasone in treating patients with primary systemic amyloidosis.
NCT00258245 ↗ Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia Completed National Cancer Institute (NCI) Phase 1 2005-05-01 RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Ascorbic acid may help arsenic trioxide work better by making cancer cells more sensitive to the drug. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Thalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. Giving arsenic trioxide and ascorbic acid together with bortezomib, thalidomide, and dexamethasone may stop the growth of and kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of arsenic trioxide when given together with ascorbic acid, bortezomib, thalidomide, and dexamethasone in treating patients with relapsed or refractory multiple myeloma or plasma cell leukemia.
NCT00258245 ↗ Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia Completed Barbara Ann Karmanos Cancer Institute Phase 1 2005-05-01 RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Ascorbic acid may help arsenic trioxide work better by making cancer cells more sensitive to the drug. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Thalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. Giving arsenic trioxide and ascorbic acid together with bortezomib, thalidomide, and dexamethasone may stop the growth of and kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of arsenic trioxide when given together with ascorbic acid, bortezomib, thalidomide, and dexamethasone in treating patients with relapsed or refractory multiple myeloma or plasma cell leukemia.
NCT00293384 ↗ Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant Completed National Cancer Institute (NCI) N/A 2004-10-01 RATIONALE: Antiemetic drugs, such as aprepitant, granisetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. PURPOSE: This clinical trial is studying how well giving aprepitant together with granisetron and dexamethasone works in preventing nausea and vomiting in patients receiving cyclophosphamide before undergoing an autologous stem cell transplant.
NCT00293384 ↗ Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant Completed Barbara Ann Karmanos Cancer Institute N/A 2004-10-01 RATIONALE: Antiemetic drugs, such as aprepitant, granisetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. PURPOSE: This clinical trial is studying how well giving aprepitant together with granisetron and dexamethasone works in preventing nausea and vomiting in patients receiving cyclophosphamide before undergoing an autologous stem cell transplant.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dexamethasone Acetate

Condition Name

Condition Name for Dexamethasone Acetate
Intervention Trials
Multiple Myeloma 6
Lymphoma 4
Cataract 4
Leukemia 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Dexamethasone Acetate
Intervention Trials
Multiple Myeloma 11
Neoplasms, Plasma Cell 9
Cataract 7
Leukemia 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Dexamethasone Acetate

Trials by Country

Trials by Country for Dexamethasone Acetate
Location Trials
United States 163
France 16
Canada 9
Spain 7
Brazil 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Dexamethasone Acetate
Location Trials
New York 14
Massachusetts 12
California 11
Texas 9
Florida 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Dexamethasone Acetate

Clinical Trial Phase

Clinical Trial Phase for Dexamethasone Acetate
Clinical Trial Phase Trials
Phase 4 21
Phase 3 10
Phase 2/Phase 3 3
[disabled in preview] 41
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Dexamethasone Acetate
Clinical Trial Phase Trials
Completed 30
Recruiting 15
Terminated 9
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Dexamethasone Acetate

Sponsor Name

Sponsor Name for Dexamethasone Acetate
Sponsor Trials
National Cancer Institute (NCI) 7
Ocular Therapeutix, Inc. 6
M.D. Anderson Cancer Center 4
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Dexamethasone Acetate
Sponsor Trials
Other 78
Industry 36
NIH 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
AstraZeneca
Medtronic
Dow
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.